Overview
I first became interested in clinical immunology as a medical student studying autoimmune inflammatory eye disease at the National Institutes of Health. Since then, I have been inspired to understand what causes autoimmunity and immune deficiency disorders in order to improve the quality of life for my patients. I see patients with multiple complex immune disorders with particular expertise in autoimmune and Rheumatoid arthritis, primary Sjogren's syndrome, and the immunodeficiency disorders Common Variable Immunodeficiency (CVID), Adenosine Deaminase Deficiency (ADA) disorders, and WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis). My research investigates immune targets that may impact either the development of immune disease or identify new therapies for patients. The goal is to help us understand why and how immunologic diseases develop so that we may better treat them.
Current Appointments & Affiliations
In the News
View All News
Recent Publications
Comment on: Use of Plerixafor for Short-Term Management of Leukopenia in a Pediatric Patient With WHIM Syndrome.
Journal Article Pediatr Blood Cancer · July 2025 Full text Link to item CiteClinicopathologic Features and the Spectrum of Myelokathexis in Warts, Hypogammaglobulinemia, Infections, Myelokathexis Syndrome.
Journal Article Lab Invest · April 14, 2025 Warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome is a rare primary immunodeficiency disorder predominantly caused by germline CXCR4 variants. Bone marrow (BM) evaluation showing myelokathexis helps to establish the diagnosis of WHIM ... Full text Link to item CiteMulti-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy.
Journal Article J Clin Immunol · March 27, 2025 PURPOSE: The safety and tolerability of elapegademase (elapegademase-lvlr; Revcovi®) a PEGylated recombinant adenosine deaminase (ADA), were demonstrated in two Phase 3 clinical trials in the U.S. and Japan in patients with ADA-deficient severe combined im ... Full text Link to item CiteRecent Grants
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of mavorixafor in participants with congenital and acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infec
Clinical TrialPrincipal Investigator · Awarded by X4 Pharmaceuticals · 2025 - 2029HZNP-DAZ-303: A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Dazodalibep in participants with Sjogren's syndrome with moderate-to-severe symptom state.
Clinical TrialPrincipal Investigator · Awarded by Horizon Therapeutics Ireland DAC · 2024 - 2026HZNP-DAZ-301: A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Dazodalibep in participants with Sjogren's syndrome with moderate-to-severe systemic disease activity.
Clinical TrialPrincipal Investigator · Awarded by Horizon Therapeutics Ireland DAC · 2024 - 2026View All Grants